Regulatory
Lilly’s New Alzheimer’s Drug Suffers Setback as Phase 3 Results Fall Short of Expectations
2023-03-10
Reata’s Groundbreaking Therapy for an Ultra-rare Neuromuscular Disease Secures FDA Approval
2023-03-02